Condition: IBD (Inflammatory Bowel Disease) · Crohn Disease (CD) · Ulcerative Colitis (UC) · Sponsor: Dalia Lartey
Our main objective is to evaluate the feasibility of 68Ga-FAPi PET/CT in detecting intestinal fibrosis in patients with IBD. To this end, we will determine 68Ga-FAPi uptake in IBD in relation to cellular FAP expression in intestinal biopsies and resection specimens.
This description comes directly from the study's public registry record.
Dalia A Lartey, MD · +31205668160 · d.a.lartey@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Amsterdam UMC | Amsterdam, North Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06604260